| Description |
1 online resource (xv, 110 pages). |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
| Series |
Technical report ; TR-1247-AMGEN |
|
Technical report (Rand Corporation) ; TR-1247-AMGEN.
|
| Bibliography |
Includes bibliographical references. |
| Summary |
This report aims to inform the development of quality indicators for postmenopausal osteoporosis management through: (a) assessing the evidence for screening and diagnosis of osteoporosis and related risk factors, and for prevention and treatment of osteoporosis and osteoporosis-related fractures; (b) describing current practice for managing postmenopausal osteoporosis in Europe; and (c) highlighting existing gaps in the evidence base and management practices in Europe. Analyses involved a comprehensive review of reviews regarding the screening and diagnosis of osteoporosis and related risk factors and the prevention and treatment of osteoporosis and osteoporosis-related fractures. While this identified a well developed evidence base on the effects of selected treatments on clinical outcomes of postmenopausal osteoporosis and associated fractures, and on the usefulness of selected simple risk factor assessment tools to identify postmenopausal women who would benefit from further diagnostic assessment, uncertainties remain regarding for example the optimal use of pharmacological interventions for preventive purposes and the effectiveness of population-based screening. We also carried out case study reviews of current practices for managing postmenopausal osteoporosis in England, France, Germany and Spain. We identify a need for the establishment of routine monitoring systems to enable better understanding of contemporary patterns and trends and identify care gaps in the management of postmenopausal osteoporosis and associated fractures. Such analyses are crucial to inform targeted strategies and policies to effectively address the burden of osteoporosis and associated fractures, which is sizable and set to increase across Europe. We set out considerations as a starting point for the further development of quality measures for postmenopausal osteoporosis in Europe. |
| Note |
Online resource; title from PDF title page (viewed on July 9, 2012). |
| Contents |
Introduction -- The diagnosis, prevention and treatment of postmenopausal osteoporosis -- Managing postmenopausal osteoporosis in Europe -- Informing the development of quality indicators for the management of postmenopausal osteoporosis -- Appendix A: Overview of guidelines in place in four countries -- Appendix B: Interview topic guide. |
| Subject |
Osteoporosis in women -- Europe.
|
|
Evidence-based medicine -- Europe.
|
|
Evidence-based medicine.
|
|
Risk assessment.
|
|
Outcome assessment (Medical care)
|
|
Europe.
|
|
Osteoporosis, Postmenopausal -- therapy |
|
Evidence-Based Medicine |
|
Risk Assessment |
|
Treatment Outcome |
|
Quality Indicators, Health Care |
|
Europe |
|
Ostéoporose chez la femme -- Europe.
|
|
Médecine factuelle -- Europe.
|
|
Médecine factuelle.
|
|
Évaluation du risque.
|
|
Évaluation des résultats (Soins médicaux)
|
|
Europe.
|
|
risk assessment.
|
|
Risk assessment
|
|
Outcome assessment (Medical care)
|
|
Evidence-based medicine
|
|
Osteoporosis in women
|
|
Europe https://id.oclc.org/worldcat/entity/E39PBJxCxPbbk4CPJDQJb4r6rq
|
| Genre/Form |
Review |
| Added Author |
Conklin, Annalijn.
|
|
RAND Europe.
|
|
Amgen Inc.
|
| ISBN |
9780833079848 |
|
0833079840 |
| Report No. |
RAND/TR-1247-AMGEN |
| Standard No. |
NLM 101586328 |
|
AU@ 000051550525 |
|
GBVCP 1008657484 |
|
